BR112022020974A2 - Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk - Google Patents

Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk

Info

Publication number
BR112022020974A2
BR112022020974A2 BR112022020974A BR112022020974A BR112022020974A2 BR 112022020974 A2 BR112022020974 A2 BR 112022020974A2 BR 112022020974 A BR112022020974 A BR 112022020974A BR 112022020974 A BR112022020974 A BR 112022020974A BR 112022020974 A2 BR112022020974 A2 BR 112022020974A2
Authority
BR
Brazil
Prior art keywords
respiratory distress
acute respiratory
syndrome
distress syndrome
treatment
Prior art date
Application number
BR112022020974A
Other languages
English (en)
Inventor
Langrish Claire
Thomas Dolca
Wolff Stefani
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of BR112022020974A2 publication Critical patent/BR112022020974A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

TRATAMENTO DA SÍNDROME DA ANGÚSTIA RESPIRATÓRIA AGUDA E OUTROS DISTÚRBIOS ENVOLVENDO TEMPESTADE DE CITOCINA USANDO INIBIDORES DE BTK. Métodos de tratamento de uma doença escolhida entre síndrome da angústia respiratória aguda, sepse, lesão pulmonar aguda induzida por sepse, dano alveolar difuso, síndrome de ativação de macrófagos, linfo-histiocitose hemofagocítica secundária, síndrome de liberação de citocinas e síndrome de resposta inflamatória sistêmica em um mamífero usando uma quantidade terapeuticamente eficaz de um inibidor de BTK molecular pequeno são descritos.
BR112022020974A 2020-04-22 2021-04-21 Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk BR112022020974A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063013784P 2020-04-22 2020-04-22
PCT/US2021/028381 WO2021216696A1 (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Publications (1)

Publication Number Publication Date
BR112022020974A2 true BR112022020974A2 (pt) 2022-12-06

Family

ID=75919390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020974A BR112022020974A2 (pt) 2020-04-22 2021-04-21 Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk

Country Status (12)

Country Link
US (1) US20230158031A1 (pt)
EP (1) EP4138836A1 (pt)
JP (1) JP2023522693A (pt)
KR (1) KR20230015346A (pt)
CN (1) CN115443136A (pt)
AU (1) AU2021261327A1 (pt)
BR (1) BR112022020974A2 (pt)
CA (1) CA3175788A1 (pt)
IL (1) IL297316A (pt)
MX (1) MX2022013164A (pt)
TW (1) TW202206076A (pt)
WO (1) WO2021216696A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU2012255860C1 (en) 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP2892900B1 (en) 2012-09-10 2017-08-16 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
US9637486B2 (en) * 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015149056A1 (en) * 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors

Also Published As

Publication number Publication date
CN115443136A (zh) 2022-12-06
MX2022013164A (es) 2022-11-30
AU2021261327A1 (en) 2022-12-22
CA3175788A1 (en) 2021-10-28
WO2021216696A1 (en) 2021-10-28
KR20230015346A (ko) 2023-01-31
JP2023522693A (ja) 2023-05-31
US20230158031A1 (en) 2023-05-25
IL297316A (en) 2022-12-01
TW202206076A (zh) 2022-02-16
EP4138836A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
CY1123504T1 (el) Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι χρησεως αυτων
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
CY1121398T1 (el) Συνδυασμος αδαπαλενης και υπεροξειδιου του βενζοϋλιου για την αγωγη των βλαβων της ακμης
CY1119546T1 (el) Συνδυαστικη θεραπεια υποκατεστημενης οξαζολιδινονης
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
CY1114363T1 (el) Ανθελμινθικος συνδυασμος
AR066585A1 (es) Nuevo producto y su uso y fabricacion
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
EA202193012A1 (ru) Способы введения определенных ингибиторов vmat2
ECSP055854A (es) Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
BR112022020974A2 (pt) Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk
CR20110184A (es) Inhibidores de la integrasa del vih
CL2022000933A1 (es) Manejo temprano y prevención de sepsis y síndrome similar a sepsis
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
WO2019204332A3 (en) Pak4 inhibitors and methods of use
CL2023000679A1 (es) Métodos y composiciones relacionados con la evaluación de afecciones inflamatorias relacionadas con la fecundidad
BR112022019090A2 (pt) Inibidores de c5a para o tratamento de infecção por coronavírus
TWI801006B (zh) 紅肉蘋果和櫻桃李組合物及其在抗血栓方面的應用
TWI801004B (zh) 紅肉蘋果和櫻桃李組合物及其在降血脂方面的應用
BR112022023187A2 (pt) Compostos para o tratamento da sars
EP4119165A4 (en) NOVEL 3,5-DIAMINOBENZOIC ACID COMPOUND AS WELL AS PIN1 INHIBITOR AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES